Description: CB-103 is a novel and potent γ-secretase inhibitor that is currently being investigated in Phase-1 dose escalation in cancer patients. CB-103 produces Notch loss-of-function phenotypes in flies and mice and inhibits the growth of human breast cancer and leukemia xenografts, notably without causing the dose-limiting intestinal toxicity associated with other Notch inhibitors.

纯度：≥98%

CAS：218457-67-1